Results 301 to 310 of about 456,798 (336)

Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review.

JAMA cardiology, 2021
Importance In the last decade, immune checkpoint inhibitors (ICIs) have been approved for the treatment of many cancer types. Immune checkpoint inhibitor-associated myocarditis has emerged as a significant and potentially fatal adverse effect ...
L. Lehmann, J. Cautela, Nicolas L. Palaskas, Alan H. Baik, Wouter C. Meijers, Y. Allenbach, J. Alexandre, T. Rassaf, O. Müller, M. Aras, Aarti H Asnani, A. Deswal, M. Laufer-Perl, F. Thuny, M. Kerneis, S. Hayek, S. Ederhy, J. Salem, J. Moslehi   +18 more
semanticscholar   +1 more source

Immune Checkpoint Inhibitor-Associated Nephrotoxicity

Nephron, 2023
<b><i>Context:</i></b> The clinical indications for immune checkpoint inhibitors (ICIs) are rapidly expanding. However, adverse events affecting multiple organs, including kidneys leading to ICI-associated acute kidney injury (AKI), remain a significant challenge with ICI therapy.
Omar Mamlouk, Farhad R. Danesh
openaire   +2 more sources

Immune checkpoint inhibitors: current status

BMJ Supportive & Palliative Care, 2021
The use of immune checkpoint inhibitors (ICIs) is growing rapidly in oncology and palliative care clinicians and other generalists will increasingly see patients who are receiving, or who have received ICI. For optimal care, it is important that clinicians have a basic understanding of the unique nature of ICI as anticancer treatments, including ...
Ana Filipa Palma dos Reis, Ivo Hennig, Andrew Wilcock   +2 more
openaire   +2 more sources

Immune checkpoint inhibitor-related hypophysitis

Best Practice & Research Clinical Endocrinology & Metabolism, 2022
Immune checkpoint inhibitors (ICIs) have been recently proposed as a strategy for treating anti-malignant neoplasms. However, this treatment leads to immune-related adverse events (irAEs) such as autoimmune endocrinopathy. Early diagnosis and appropriate treatment of ICI-related hypophysitis are essential as it can manifest as a life-threatening ...
Tadashi, Mizukoshi, Hidenori, Fukuoka, Yutaka, Takahashi   +2 more
openaire   +2 more sources

Radiotherapy, immunity, and immune checkpoint inhibitors

The Lancet Oncology
Radiotherapy exerts immunostimulatory and immunosuppressive effects, both locally, within the irradiated tumour microenvironment, and systemically, outside the radiation field. Inspired by preclinical data that showed synergy between radiotherapy and immune checkpoint inhibitors, multiple clinical trials were initiated with the hypothesis that combined
Connor, Lynch, Sean P, Pitroda, Ralph R, Weichselbaum   +2 more
openaire   +2 more sources

Immune Checkpoint Inhibitor–Induced Lipodystrophy

JAMA Dermatology
This case series describes lipodystrophy, a rare adverse event associated with immune checkpoint inhibitor therapy.
Riganti J., Torre A. C., Sollena P., Koumaki D., Freites-Martinez A., Delyon J., Communie A., Starace M., Rapparini L., Lallas A., Mavroudis D., Suzanne D., Mazzuoccolo L. D., Bobos M., Sibaud V., Apalla Z.   +15 more
openaire   +3 more sources

Immune checkpoint inhibitors and vasculitis

Current Opinion in Rheumatology, 2020
Purpose of review Clinical use of immune checkpoint inhibitor (ICI) therapy has revolutionized the therapeutic landscape of cancer. By activating the immune system using monoclonal anti-CTLA-4 and PD(L)-1 antibodies, remission can be induced in previously terminal cancers. However, these breakthroughs come at a price.
Patrick, Boland, Jacqueline, Heath, Sabina, Sandigursky   +2 more
openaire   +2 more sources

Immune Checkpoint Inhibitors–Related Cardiotoxicity

American Journal of Therapeutics, 2020
Background: Immunotherapy is a significant breakthrough in cancer therapy in the last decade. Immunotherapy is better tolerated compared with chemotherapy. However, it does have side effects, and one of the rare and serious side effects of immunotherapy is cardiotoxicity.
Venu Madhav, Konala, Sreedhar, Adapa, Wilbert S, Aronow   +2 more
openaire   +2 more sources

Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data

Supportive Care in Cancer, 2023
D. Guven, E. Erul, Yunus Kaygusuz, Baran Akagunduz, S. Kılıçkap, R. De Luca, A. Rizzo   +6 more
semanticscholar   +1 more source

Immune Checkpoint Inhibitors-Induced Colitis

2018
Immune checkpoint inhibitors (ICIs) have shown significant benefit in cancer patients, but are associated with immune-related adverse events (irAEs), that can affect the gastrointestinal tract resulting in diarrhea and colitis. IrAEs range from mild self-limiting to severe life-threatening disease, which potentially limit the use of these medications ...
Yun, Tian, Hamzah, Abu-Sbeih, Yinghong, Wang   +2 more
openaire   +2 more sources